Premium
Development of oncolytic virotherapy for the treatment of oral cancer – At the waiting stage for clinical use
Author(s) -
Yura Yoshiaki,
Hamada Masakazu
Publication year - 2016
Publication title -
oral science international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.256
H-Index - 13
eISSN - 1881-4204
pISSN - 1348-8643
DOI - 10.1016/s1348-8643(16)30016-7
Subject(s) - oncolytic virus , virotherapy , cancer , medicine , head and neck cancer , virus , cancer research , oncology , immunology , virology
Oncolytic virotherapy originated from the finding that virus‐infected tumor cells are destroyed by the cytopathic effects of viruses. Cell death induced by viral infections in tumor tissues also promotes inherent tumor immunity in cancer patients. Several DNA and RNA viruses have been proposed as candidates for this treatment through in vitro and in vivo studies as well as clinical trials. Oral cancer is often accompanied by lymph node metastasis, resulting in worse patient prognoses. Some oncolytic viruses have been investigated for their therapeutic effects on patients with advanced head and neck cancer, including oral cancer. Oncolytic virotherapy is expected to become a treatment modality that will be essential for controlling chemoradio‐resistant oral cancer.